Akari Therapeutics (AKTX) Earnings Analysis
Akari Therapeutics (AKTX) next reports earnings on 2026-08-18, consensus EPS -1.04 USD. Last quarter (2026-05-19) it missed with EPS -9.74 USD vs -1.33 USD est (-632.3%). It has beaten estimates in 2/7 recent quarters (29%). Trailing P/E -0.01.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does AKTX next report earnings?
| Next earnings date | 2026-08-18 |
|---|---|
| Consensus EPS estimate | -1.04 USD |
| Revenue estimate | n/a |
AKTX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-19 | -9.74 USD | -1.33 USD | -632.3% | Miss |
| 2026-04-07 | -2.99 USD | -1.8 USD | -66.1% | Miss |
| 2025-11-13 | -0.1 USD | -0.04 USD | -150% | Miss |
| 2025-08-13 | -0.06 USD | -0.09 USD | +33.3% | Beat |
| 2025-05-14 | -0.135 USD | n/a | n/a | n/a |
| 2025-04-14 | -0.17 USD | -1 USD | +83% | Beat |
| 2024-11-18 | -9.6 USD | -0.6 USD | -1500% | Miss |
| 2024-08-18 | -3.2 USD | -1 USD | -220% | Miss |
Beat rate: 2/7 (29%) over reported quarters with consensus data.
AKTX valuation and analyst view
| Trailing P/E | -0.01 |
|---|---|
| Trailing EPS | -1,333.07731 USD |
| Price / book | 0.01 |
| Dividend yield | 0.00% |
| Market cap | 0.01B |
| Analyst consensus | Buy (7 buy / 1 hold / 0 sell) |
| Avg price target | 30 USD |
Related research pages
Frequently asked questions
When is Akari Therapeutics (AKTX)'s next earnings date?
Akari Therapeutics is next scheduled to report on 2026-08-18, with a consensus EPS estimate of -1.04 USD.
Did AKTX beat earnings last quarter?
In its 2026-05-19 report, AKTX posted EPS of -9.74 USD versus a -1.33 USD estimate — a miss of 632.3%.
What is AKTX's earnings track record?
Over the last 7 reported quarters with consensus data, AKTX beat estimates 2 times (29%).
What is AKTX's current P/E ratio and EPS?
AKTX trades at a trailing P/E of -0.01 on trailing EPS of -1333.077313541229 USD.
What do analysts rate AKTX?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 30 USD.